Ginkgo Bioworks (DNA) Competitors $11.13 +0.43 (+4.02%) (As of 03:09 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNA vs. AMRX, PTGX, IDYA, CNTA, LBPH, WVE, RXRX, CGON, APGE, and AKROShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Amneal Pharmaceuticals (AMRX), Protagonist Therapeutics (PTGX), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Longboard Pharmaceuticals (LBPH), Wave Life Sciences (WVE), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Apogee Therapeutics (APGE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Amneal Pharmaceuticals Protagonist Therapeutics IDEAYA Biosciences Centessa Pharmaceuticals Longboard Pharmaceuticals Wave Life Sciences Recursion Pharmaceuticals CG Oncology Apogee Therapeutics Akero Therapeutics Ginkgo Bioworks (NYSE:DNA) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is DNA or AMRX more profitable? Amneal Pharmaceuticals has a net margin of -6.88% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-298.78% -58.54% -34.24% Amneal Pharmaceuticals -6.88%-346.26%4.85% Do insiders and institutionals hold more shares of DNA or AMRX? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, DNA or AMRX? Ginkgo Bioworks has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Does the media refer more to DNA or AMRX? In the previous week, Ginkgo Bioworks had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Ginkgo Bioworks and 5 mentions for Amneal Pharmaceuticals. Ginkgo Bioworks' average media sentiment score of 1.05 beat Amneal Pharmaceuticals' score of 1.02 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DNA or AMRX? Ginkgo Bioworks presently has a consensus target price of $4.58, indicating a potential downside of 58.71%. Amneal Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 25.00%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has higher valuation & earnings, DNA or AMRX? Amneal Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$217.11M2.93-$892.87M-$13.08-0.85Amneal Pharmaceuticals$2.39B1.04-$83.99M-$0.68-11.76 Does the MarketBeat Community prefer DNA or AMRX? Ginkgo Bioworks received 9 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 93.75% of users gave Amneal Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Amneal PharmaceuticalsOutperform Votes1593.75% Underperform Votes16.25% SummaryAmneal Pharmaceuticals beats Ginkgo Bioworks on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyTwo halves of the same soul…What I’m about to tell you is a story that is so ironic and unexpected that it’s almost inconceivable. It’s the story of two men, who live 2,400 miles away from one another. One is in California. The other, Ohio. And now, for the first time, the lives of these two men have intersected on a single investment.Click here to see what is happening Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$650.09M$3.02B$5.25B$20.15BDividend YieldN/A1.86%5.66%3.47%P/E Ratio-0.8643.32128.3243.29Price / Sales2.99471.341,260.9018.35Price / CashN/A171.1035.1718.56Price / Book0.524.014.835.68Net Income-$892.87M-$41.68M$117.36M$985.83M7 Day Performance16.18%2.45%1.05%-0.66%1 Month Performance33.22%0.83%-0.44%1.25%1 Year PerformanceN/A34.42%33.47%23.54% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.0738 of 5 stars$11.13+4.0%$4.58-58.9%N/A$639.74M$217.11M-0.851,218Positive NewsAMRXAmneal Pharmaceuticals3.0403 of 5 stars$8.18-3.2%$10.00+22.2%+59.9%$2.53B$2.39B0.007,700Positive NewsPTGXProtagonist Therapeutics3.6645 of 5 stars$40.96-2.6%$53.78+31.3%+98.9%$2.44B$60M15.81125Analyst ForecastIDYAIDEAYA Biosciences4.2063 of 5 stars$27.62-0.6%$53.67+94.3%-10.2%$2.39B$3.92M-11.9780Positive NewsCNTACentessa Pharmaceuticals4.1275 of 5 stars$18.02-3.5%$25.83+43.4%+171.6%$2.38B$6.85M0.0072LBPHLongboard Pharmaceuticals1.3695 of 5 stars$59.98+0.0%$59.56-0.7%+1,221.1%$2.34BN/A-26.9020Positive NewsWVEWave Life Sciences4.9835 of 5 stars$15.15-0.8%$22.22+46.7%+236.5%$2.31B$113.31M0.00240Positive NewsRXRXRecursion Pharmaceuticals1.427 of 5 stars$8.01+21.5%$9.25+15.5%+8.8%$2.30B$44.58M-5.24400High Trading VolumeCGONCG Oncology1.9316 of 5 stars$33.82-2.2%$63.88+88.9%N/A$2.29B$200,000.000.0061APGEApogee Therapeutics2.5419 of 5 stars$49.24-1.5%$83.88+70.3%+128.4%$2.22BN/A0.0091AKROAkero Therapeutics4.1791 of 5 stars$30.81-1.0%$46.83+52.0%+56.6%$2.15BN/A0.0030Positive News Related Companies and Tools Related Companies Amneal Pharmaceuticals Competitors Protagonist Therapeutics Competitors IDEAYA Biosciences Competitors Centessa Pharmaceuticals Competitors Longboard Pharmaceuticals Competitors Wave Life Sciences Competitors Recursion Pharmaceuticals Competitors CG Oncology Competitors Apogee Therapeutics Competitors Akero Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:DNA) was last updated on 12/10/2024 by MarketBeat.com Staff From Our PartnersTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | SponsoredThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
